This suggests that AOD 9604 may potentially augment the anti-cancer potency of doxorubicin while possibly minimizing unintended actions associated with non-target tissue exposure
doi:10.1152/ajpendo.2000.279.3.E501 Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R
All products on this site are supplied for laboratory research, development or analytical use only
Cycle Length and Long-Term Use: Initial assessment cycles typically run 12-16 weeks, which aligns with the duration of clinical trials and allows adequate time to evaluate metabolic response and body composition changes
While HGH exerts multiple effects on muscle, bone, and glucose regulation, AOD-9604 specifically targets fat metabolism